Inflammatory regulatory protein identified by researchers
Posted: 22 November 2019 | Victoria Rees (Drug Target Review) | 1 comment
A study has discovered that the PKM2 protein plays a role in regulating immune cells and blocking this could be a potential treatment for inflammatory diseases.
Researchers have revealed the role of a protein in the regulation of immune cell types involved in multiple inflammatory diseases. According to the team, their findings present a drug target for these conditions.
The study was conducted at Trinity College Dublin, Ireland.
The PKM2 protein was identified as a potential therapeutic target for treating a range of diseases mediated by over-active immune cells, such as psoriasis and multiple sclerosis (MS).
Reduce preclinical failures with smarter off-target profiling
24 September 2025 | 15:00PM BST | FREE Webinar
Join this webinar to hear from Dr Emilie Desfosses as she shares insights into how in vitro and in silico methods can support more informed, human-relevant safety decisions -especially as ethical and regulatory changes continue to reshape preclinical research.
What you’ll learn:
- Approaches for prioritizing follow-up studies and refining risk mitigation strategies
- How to interpret hit profiles from binding and functional assays
- Strategies for identifying organ systems at risk based on target activity modulation
- How to use visualization tools to assess safety margins and compare compound profiles
Register Now – It’s Free!
The researchers discovered that PKM2 acts as an ‘on’ switch for the Th17 and Th1 immune cells via experiments in murine and human cells in vitro.
The team also treated the immune cells with TEPP-46, an allosteric activator. This strongly reduced its PKM2 activity by inhibiting essential signalling pathways and was successful at limiting inflammation.
Lead author Dr Stefano Angiari said: “Th17 and Th1 cells are very important for the damage that happens in autoimmune diseases such as psoriasis and MS. We have found that interfering with PKM2 blocks these cells and limits inflammation.”
Lead researcher Professor Luke O’Neill added: “PKM2 is a fascinating protein that has a role in how cells use glucose for energy, but it also moonlights in the immune system, where we have found it can be especially troublesome. We are currently exploring it as a new target for therapies that might work in patients with diseases like psoriasis and multiple sclerosis, where treatment options are limited.”
The findings were published in Cell Metabolism.
Related topics
Disease Research, Drug Targets, Protein, Research & Development
Related conditions
inflammation, Multiple Sclerosis (MS), Psoriasis
Related organisations
Trinity College Dublin
Related people
Dr Stefano Angiari, Professor Luke O'Neill
Articles like this are essentially saying, “Studies show a new pathway in a highly non-linear system just might be able to control the system dynamics in a linear fashion, thereby proving we are incapable of understanding the probabilities that non-linear systems of importance are operating in a linear regime in the areas of our concern.